← Back to Search

P2Y12 receptor inhibitor

Ticagrelor 90mg for Acute Coronary Syndrome (TC4 Trial)

Phase 4
Waitlist Available
Led By James Brophy, MD, PhD
Research Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months
Awards & highlights

TC4 Trial Summary

This trial is being done to determine if ticagrelor + aspirin (T+A) or clopidogrel and aspirin (C+A) is the most effective and safest dual antiplatelet therapy for our patients.

Eligible Conditions
  • Acute Coronary Syndrome

TC4 Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
The (The hazard ratio for the number of participants that develop the outcome, a composite of cardiovascular-related mortality, myocardial infarction (MI), or stroke) stratified by sex
The (The hazard ratio for the number of participants that develop the outcome, a composite of cardiovascular-related mortality, myocardial infarction (MI), or stroke) stratified by sex.
The hazard ratio for the number of participants that develop the outcome, a composite of cardiovascular-related mortality, myocardial infarction (MI), or stroke.
+6 more

Side effects data

From 2021 Phase 3 trial • 76 Patients • NCT03649711
39%
Bruise
17%
Fatigue
4%
Acidity
4%
Dyspnea
100%
80%
60%
40%
20%
0%
Study treatment Arm
Arm: Active Comparator: CKD-Clopidogrel
Experimental: CKD-Ticagrelor
Arm: Active Comparator: Control-ticagrelor

TC4 Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Ticagrelor 90mgExperimental Treatment2 Interventions
Ticagrelor: 180 mg loading dose followed by 90 mg BID. Aspirin: 325 loading dose followed by 81 mg daily.
Group II: Clopidogrel 75mgActive Control2 Interventions
Clopidogrel: 300 mg loading dose followed by 75 mg daily. Aspirin: 325 loading dose followed by 81 mg daily.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Acetylsalicylic acid
FDA approved
Ticagrelor
FDA approved

Find a Location

Who is running the clinical trial?

McGill University Health Centre/Research Institute of the McGill University Health CentreLead Sponsor
442 Previous Clinical Trials
158,136 Total Patients Enrolled
1 Trials studying Acute Coronary Syndrome
65 Patients Enrolled for Acute Coronary Syndrome
Canadian Institutes of Health Research (CIHR)OTHER_GOV
1,341 Previous Clinical Trials
26,451,675 Total Patients Enrolled
9 Trials studying Acute Coronary Syndrome
8,921 Patients Enrolled for Acute Coronary Syndrome
James Brophy, MD, PhDPrincipal InvestigatorMcGill University Health Centre/Research Institute of the McGill University Health Centre

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes
James Brophy 2018. "Ticagrelor Compared to Clopidogrel in Acute Coronary Syndromes". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04057300.
~160 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top